Xenografting of Cancer Cell Lines for In Vivo Screening of the Therapeutic Potential of HDAC Inhibitors

Daniel Nettersheim; Sina Jostes; Hubert Schorle

doi:10.1007/978-1-4939-6527-4_15

Xenografting of Cancer Cell Lines for In Vivo Screening of the Therapeutic Potential of HDAC Inhibitors

Methods Mol Biol. 2017:1510:211-215. doi: 10.1007/978-1-4939-6527-4_15.

Authors

Daniel Nettersheim¹, Sina Jostes², Hubert Schorle²

Affiliations

¹ Department of Developmental Pathology, Institute of Pathology, University Medical School Bonn, Sigmund-Freud-Strasse 25, 53127, Bonn, Germany. Daniel.Nettersheim@ukb.uni-bonn.de.
² Department of Developmental Pathology, Institute of Pathology, University Medical School Bonn, Sigmund-Freud-Strasse 25, 53127, Bonn, Germany.

PMID: 27761823
DOI: 10.1007/978-1-4939-6527-4_15

Abstract

Histone deacetylase inhibitor application is lethal to many cancer types. To screen for the therapeutic potential of HDIs it is necessary to analyze their ability to target and kill cancer cells in vivo. Here, we describe the xenografting of (germ cell) cancer cell lines into the flank of nude mice and the subsequent intravenous application of HDIs.

Keywords: Cancer cell lines; HDAC inhibitors; In vivo vein injection; Therapy; Xenografting.

MeSH terms

Animals
Antineoplastic Agents / pharmacology*
Cell Line, Tumor
Collagen / pharmacology
Culture Media / chemistry
Drug Combinations
Histone Deacetylase Inhibitors / pharmacology*
Histone Deacetylases / genetics*
Histone Deacetylases / metabolism
Humans
Injections, Intravenous
Laminin / pharmacology
Mice
Mice, Nude
Proteoglycans / pharmacology
Transplantation, Heterologous
Xenograft Model Antitumor Assays*

Substances

Antineoplastic Agents
Culture Media
Drug Combinations
Histone Deacetylase Inhibitors
Laminin
Proteoglycans
matrigel
Collagen
Histone Deacetylases